"Breakthrough Cancer Treatment Unveiled by Yale Researchers"

Yale researchers have discovered that cancer cells with extra chromosomes rely on those additional chromosomes for tumor growth, and removing them halts tumor formation. The study, published in the journal Science, suggests that selectively targeting these extra chromosomes may offer a new avenue for treating cancer. The researchers used the gene-engineering technique CRISPR to develop a new approach called ReDACT, which successfully eliminated aneuploidy in melanoma, gastric cancer, and ovarian cell lines. The findings indicate that aneuploidy may function as a therapeutic target for cancer, potentially allowing for targeted treatment while minimizing harm to normal cells. Further research is needed before this approach can be tested in clinical trials.